WO2011083147A1 - Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène - Google Patents

Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène Download PDF

Info

Publication number
WO2011083147A1
WO2011083147A1 PCT/EP2011/050183 EP2011050183W WO2011083147A1 WO 2011083147 A1 WO2011083147 A1 WO 2011083147A1 EP 2011050183 W EP2011050183 W EP 2011050183W WO 2011083147 A1 WO2011083147 A1 WO 2011083147A1
Authority
WO
WIPO (PCT)
Prior art keywords
wavel
wave1
activity
antagonist
inhibitor
Prior art date
Application number
PCT/EP2011/050183
Other languages
English (en)
Inventor
Sylvia Knapp
Ulrich Matt
Omar Sharif
Original Assignee
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh filed Critical Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh
Publication of WO2011083147A1 publication Critical patent/WO2011083147A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

La présente invention concerne des antagonistes/inhibiteurs de WAVE1 (protéine homologue de la verproline de la famille des protéines du syndrome de Wiskott-Aldrich 1) pour utilisation dans la prévention ou le traitement d'une infection causée par un agent pathogène et/ou dans la prévention ou le traitement d'une maladie inflammatoire associée à des phospholipides oxydés (OxPL) se développant en réponse à une infection causée par un agent pathogène. De plus, la présente invention concerne la prévention d'infections secondaires consécutives à une lésion, telle qu'une blessure, une chirurgie, un traumatisme ou une inflammation où ladite lésion conduit à un taux élevé de phospholipides oxydés in vivo. La présente invention concerne en outre des antagonistes/inhibiteurs de WAVE1 qui sont co-administrés avec des antibiotiques, des médicaments antiviraux, des antioxydants et/ou des médicaments anti-inflammatoires. Dans un autre aspect, la présente invention concerne un procédé pour évaluer l'activité d'une molécule candidate suspectée d'être un antagoniste/inhibiteur de WAVE1 comprenant les étapes de : (a) préincubation facultative d'une cellule, un tissu ou un animal non humain comprenant et exprimant WAVE1 avec OxPL ; (b) mise en contact desdits cellule, tissu ou animal non humain comprenant WAVE1 avec ladite molécule candidate ; (c) détection d'une diminution d'activité WAVE1 ; et (d) sélection d'une molécule candidate qui diminue l'activité WAVE1 ; une diminution de l'activité WAVE1 étant indicatrice de la capacité de la molécule sélectionnée à améliorer, prévenir ou traiter une maladie inflammatoire associé à OxPL se développant en réponse à une infection causée par un agent pathogène et/ou prévenir, améliorer ou traiter une infection causée par un agent pathogène et/ou prévenir une infection consécutive à une lésion physiologique telle qu'une blessure, un traumatisme, une chirurgie ou une inflammation. Dans un autre aspect supplémentaire, la présente invention concerne une cellule, un tissu ou un animal non humain pour criblage et/ou validation d'un composé suspecté d'être un antagoniste/inhibiteur de WAVE1. Finalement, la présente invention concerne un kit qui est utile pour mettre en œuvre le procédé de l'invention comprenant des polynucléotides et/ou des anticorps capables de détecter l'activité de WAVE1.
PCT/EP2011/050183 2010-01-08 2011-01-07 Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène WO2011083147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10150331.6 2010-01-08
EP10150331 2010-01-08

Publications (1)

Publication Number Publication Date
WO2011083147A1 true WO2011083147A1 (fr) 2011-07-14

Family

ID=43743907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/050183 WO2011083147A1 (fr) 2010-01-08 2011-01-07 Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène

Country Status (1)

Country Link
WO (1) WO2011083147A1 (fr)

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5541109A (en) 1994-04-19 1996-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. Expression cloning of c-src SH3-domain binding proteins
WO1998019162A1 (fr) 1996-10-31 1998-05-07 Novalon Pharmaceutical Corporation Identification de medicaments au moyen de bibliotheques combinatoires complementaires
WO1998025947A1 (fr) 1996-12-11 1998-06-18 Bristol-Myers Squibb Company Systeme procaryote a deux hybrides
WO1999035494A1 (fr) 1998-01-09 1999-07-15 Cubist Pharmaceuticals, Inc. Methodes pour identifier des combinaisons de cibles et de dosages valides
WO1999051741A2 (fr) 1998-04-03 1999-10-14 Curagen Corporation Complexes de proteine lyst et proteines a interaction lyst
WO1999054728A2 (fr) 1998-04-23 1999-10-28 Karo Bio Usa, Inc. Methode permettant de prevoir la capacite de composes de moduler l'activite biologique de recepteurs
US6004746A (en) 1994-07-20 1999-12-21 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US6011013A (en) * 1997-06-20 2000-01-04 Oregon Health Sciences University Contraceptive compositions and methods
WO2000002911A2 (fr) 1998-07-10 2000-01-20 Curagen Corporation INTERACTION DE PRECURSEUR DE LA PROTEINE BETA-AMYLOIDE HUMAINE (β-APP) ET DE PROTEINE HUMAINE DU TYPE LON-PROTEASE (HsLON)
WO2000005410A2 (fr) 1998-07-22 2000-02-03 Technion Research And Development Foundation Ltd. Procede de detection d'interactions proteine-proteine et kit d'utilisation
WO2000014271A1 (fr) 1998-09-03 2000-03-16 Loma Linda University PROCEDE D'ETUDE D'INTERACTIONS DE PROTEINES $i(IN VIVO)
WO2000017221A1 (fr) 1998-09-24 2000-03-30 Duke University Procede de mesure des interactions proteine-proteine dans des cellules vivantes
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
WO2002055693A2 (fr) 2001-01-09 2002-07-18 Ribopharma Ag Procede pour inhiber l'expression d'un gene cible

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5541109A (en) 1994-04-19 1996-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. Expression cloning of c-src SH3-domain binding proteins
US6004746A (en) 1994-07-20 1999-12-21 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5574656A (en) 1994-09-16 1996-11-12 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5684711A (en) 1994-09-16 1997-11-04 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program for at least partially automatically generating chemical compounds having desired properties
WO1998019162A1 (fr) 1996-10-31 1998-05-07 Novalon Pharmaceutical Corporation Identification de medicaments au moyen de bibliotheques combinatoires complementaires
WO1998025947A1 (fr) 1996-12-11 1998-06-18 Bristol-Myers Squibb Company Systeme procaryote a deux hybrides
EP0963376A1 (fr) 1996-12-11 1999-12-15 Bristol-Myers Squibb Company Systeme procaryote a deux hybrides
US6011013A (en) * 1997-06-20 2000-01-04 Oregon Health Sciences University Contraceptive compositions and methods
WO1999035494A1 (fr) 1998-01-09 1999-07-15 Cubist Pharmaceuticals, Inc. Methodes pour identifier des combinaisons de cibles et de dosages valides
WO1999051741A2 (fr) 1998-04-03 1999-10-14 Curagen Corporation Complexes de proteine lyst et proteines a interaction lyst
WO1999054728A2 (fr) 1998-04-23 1999-10-28 Karo Bio Usa, Inc. Methode permettant de prevoir la capacite de composes de moduler l'activite biologique de recepteurs
WO2000002911A2 (fr) 1998-07-10 2000-01-20 Curagen Corporation INTERACTION DE PRECURSEUR DE LA PROTEINE BETA-AMYLOIDE HUMAINE (β-APP) ET DE PROTEINE HUMAINE DU TYPE LON-PROTEASE (HsLON)
WO2000005410A2 (fr) 1998-07-22 2000-02-03 Technion Research And Development Foundation Ltd. Procede de detection d'interactions proteine-proteine et kit d'utilisation
WO2000014271A1 (fr) 1998-09-03 2000-03-16 Loma Linda University PROCEDE D'ETUDE D'INTERACTIONS DE PROTEINES $i(IN VIVO)
WO2000017221A1 (fr) 1998-09-24 2000-03-30 Duke University Procede de mesure des interactions proteine-proteine dans des cellules vivantes
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
WO2002055693A2 (fr) 2001-01-09 2002-07-18 Ribopharma Ag Procede pour inhiber l'expression d'un gene cible

Non-Patent Citations (135)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Neuroscience", 2001, JOHN WILEY&SONS
"Methods in Yeast Genetics, A Laboratory Course Manual", 1990, COLD SPRING HARBOR LABORATORY PRESS
"Nucleic acid hybridization, a practical approach", 1985, IRL PRESS
"Organic Synthesis", WILEY
"Remington's Pharmaceutical Sciences", 1980
ALRUTZ, M. A. ET AL., MOLECULAR MICROBIOLOGY, vol. 42, no. 3, 2001, pages 689 - 703
ALTO, N. M.; SODERLING, S. H.; HOSHI, N.; LANGEBERG, L. K.; FAYOS, R.; JENNINGS, P. A.; SCOTT, J. D.: "Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring", PROC. NATL. ACAD. SCI. U.S.A., vol. 100, 2003, pages 4445 - 4450
ALTSCHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL, J. MOL. EVOL., vol. 36, 1993, pages 290 - 300
ALTSCHUL, NUCL. ACIDS RES., vol. 25, 1997, pages 3389 - 3402
AN, J ORG CHEM, vol. 66, 2001, pages 2789 - 2801
AUSUBEL: "Current Protocols in Molecular Biology", 1989, GREEN PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE
BAKER, CURR. BIOL., vol. 10, 2000, pages 1071 - 1074
BEILSTEIN: "Handbook of Organic Chemistry", SPRINGER
BERRY, BIOCHEM. SOC. TRANS., vol. 22, 1994, pages 1033 - 1036
BILLMAN-JACOBE, CURRENT OPINION IN BIOTECHNOLOGY, vol. 7, 1996, pages 500 - 4
BINDER, C.J. ET AL., NAT MED, vol. 8, 2002, pages 1218 - 1226
BIOCHEM J., vol. 400, no. 3, 15 December 2006 (2006-12-15), pages 493 - 9
BIRUKOV, K.G. ET AL., CIRC RES, vol. 95, 2004, pages 892 - 901
BITTER ET AL., METHODS IN ENZYMOLOGY, vol. 153, 1987, pages 516 - 544
BLIND, PNAS, vol. 96, 1999, pages 3606 - 3610
BOCHKOV, V.N. ET AL., NATURE, vol. 419, 2002, pages 77 - 81
BOULLIER, A. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 9163 - 9169
BRUMMELKAMP, SCIENCE, vol. 296, 2002, pages 550 - 553
BRUTLAG, COMP. APP. BIOSCI., vol. 6, 1990, pages 237 - 245
BRYN, T. ET AL., J IMMUNOL, vol. 176, 2006, pages 7361 - 7370
BRYN, T. ET AL., J LMMUNOL, vol. 176, 2006, pages 7361 - 7370
BURNS-HAMURO, L. L.; MA, Y.; KAMMERER, S.; REINEKE, U.; SELF, C.; COOK, C.; OLSON, G. L.; CANTOR, C. R.; BRAUN, A.; TAYLOR, S. S., BIOCHEM J. 2006 DEC 15, vol. 400, no. 3, pages 493 - 9
BURNS-HAMURO, L. L.; MA, Y.; KAMMERER, S.; REINEKE, U.; SELF, C.; COOK, C.; OLSON, G. L.; CANTOR, C. R.; BRAUN, A.; TAYLOR, S. S.: "Designing isoform-specific peptide disruptors of protein kinase A localization", PROC. NATL. ACAD. SCI. U.S.A., vol. 100, 2003, pages 4072 - 4077
CARLSON, C. R.; LYGREN, B.; BERGE, T.; HOSHI, N.; WONG, W.; TASKEN; SCOTT, J. D.: "Delineation of type I protein kinase a selective signaling events using an RI anchoring disruptor (RIAD)", J. BIOL. CHEM., vol. 281, 2006, pages 21535 - 21545
CARR DW; HAUSKEN ZE; FRASER ID; STOFKO-HAHN RE; SCOTT JD., J BIOL CHEM., vol. 267, no. 19, 5 July 1992 (1992-07-05), pages 13376 - 82
CARR, D.W. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTLY, vol. 267, 1992, pages 13376 - 13382
CARR, D.W. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, 1992, pages 13376 - 13382
DE FOUGEROLLES ET AL., NAT. REV. DRUG DISCOV., vol. 6, 2007, pages 443 - 453
DE OLIVEIRA, LIFE SCI, vol. 67, 2000, pages 1625 - 1637
DEI, R. ET AL., ACTA NEUROPATHOL, vol. 104, 2002, pages 113 - 122
DEJONG, CURR TROP MED CHEM, vol. 2, 2002, pages 289 - 302
DINH, H. ET AL., J LEUKOC BIOL, vol. 84, 2008, pages 1483 - 1491
DONZE, NUCLEIC ACIDS RES, vol. 30, 2002, pages E46
DORNER, BIOORG. MED. CHEM., vol. 4, 1996, pages 709 - 715
ELBASHIR, EMBO J., vol. 20, 2001, pages 6877 - 6888
ELBASHIR, METHODS, vol. 26, 2002, pages 199 - 213
ELNITSKI, GENOME RES, vol. 16, 2006, pages 1455 - 64
FAMULOK, CURR. OP. CHEM. BIOL., vol. 2, 1998, pages 320 - 327
FRIEDMAN, P. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, 2002, pages 7010 - 7020
GALLOP, JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 9, 1994, pages 1233 - 1250
GOLD, ANN. REV. BIOCHEM., vol. 64, 1995, pages 763 - 797
GRIFFITHS ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 75, 1997, pages 427 - 440
HAMPTON, M.B. ET AL., BLOOD, vol. 92, 1998, pages 3007 - 3017
HAN, ANTISENSE RES DEV, vol. 4, 1994, pages 53 - 65
HANSSON, G.K. ET AL., NAT REV IMMUNOL, vol. 6, 2006, pages 508 - 519
HANSSON, G.K., NAT REV IMMUNOL, vol. 6, 2006, pages 508 - 519
HERMANN, ANGEW CHEM INT ED ENGL, vol. 39, 2000, pages 1890 - 1904
HOCKNEY, TRENDS IN BIOTECHNOLOGY, vol. 12, 1994, pages 456 - 463
HOEBE, K. ET AL., NATURE, vol. 433, 2005, pages 523 - 527
HOLZHEIMER, R.G. ET AL., INFECTION, vol. 19, 1991, pages 447 - 452
HUNDSRUCKER, C.; KRAUSE, G.; BEYERMANN, M.; PRINZ, A.; ZIMMERMANN, B.; DIEKMANN, O.; LORENZ, D.; STEFAN, E.; NEDVETSKY, P.; DATHE,: "High-affinity AKAP76-protein kinase A interaction yields novel protein kinase A anchoring disruptor peptides", BIOCHEM. J., vol. 396, 2006, pages 297 - 306
IMAI, Y. ET AL., CELL, vol. 133, 2008, pages 235 - 249
JEFFREY, MOL. CELL. BIOL., vol. 7, no. 2, 1987, pages 725 - 737
KAKSONEN, M. ET AL., NATURE REVIEWS, vol. 7, 2006, pages 404 - 414
KANDIMALLA, GENE, vol. 149, 1994, pages 115 - 121
KANG R ET AL: "WAVE1 regulates Bcl-2 localization and phosphorylation in leukemia cells.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K JAN 2010 LNKD- PUBMED:19890377, vol. 24, no. 1, 5 November 2009 (2009-11-05), published online 5 November 2009, pages 177 - 186, XP002630097, ISSN: 1476-5551 *
KASUS-JACOBI, ONCOGENE, vol. 19, 2000, pages 2052 - 2059
KIM, Y. ET AL., NATURE, vol. 442, 2006, pages 814 - 817
KNAPP SYLVIA ET AL: "Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo", JOURNAL OF IMMUNOLOGY, vol. 178, no. 2, January 2007 (2007-01-01), pages 993 - 1001, XP002630096, ISSN: 0022-1767 *
KNAPP, S. ET AL., J IMMUHOL, vol. 178, 2007, pages 993 - 1001
KNAPP, S. ET AL., J IMMUNOL, vol. 178, 2007, pages 993 - 1001
KNAPP, S. ET AL., J LMMUNOL, vol. 178, 2007, pages 993 - 1001
KNAPP, S. ET AL., J LMMUNOL, vol. I78, 2007, pages 993 - 1001
KNAPP, S. ET AL., JLMMUNOL, vol. 178, 2007, pages 993 - 1001
KOLB: "High throughput screening: the discovery of bioactive substances", 1997, MARCEL DEKKER, article "A homogenius time resolved fluorescence method for drug discovery", pages: 345 - 360
LA COUNT, BIOCHEM. PARAS., vol. 111, 2000, pages 67 - 76
LAGLER, H. ET AL., JIINMUNOL, vol. 183, 2009, pages 2027 - 2036
LEAMAN, METH ENZYMOL, vol. 18, 1999, pages 252 - 265
LEUNG; WHITTAKER, PHARMACOL THER., vol. 107, no. 2, August 2005 (2005-08-01), pages 222 - 39
MANOHARAN, CURR OPIN CHEM BIOL., vol. 8, no. 6, December 2004 (2004-12-01), pages 570 - 9
MARIE, CURR. BIOL., vol. 10, 2000, pages 289 - 292
MATT, U. ET AL., JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE), OR INFLAMMATORY BRAIN LESIONS, 2009
MAYER, PNAS, vol. 98, 2001, pages 4961 - 4965
METHODS IN ENZYMOLOGY, vol. 153, 1987, pages 385 - 516
MILLER, Y.I. ET AL., MOL BIOL CELL, vol. 14, 2003, pages 4196 - 4206
MONROE, IMMUNITY, vol. 11, 1999, pages 201 - 212
MURCH, A.R. ET AL., J PATHOL, vol. 144, 1984, pages 81 - 87
MURCH, A.R., J PATHOL, vol. 144, 1984, pages 81 - 87
MUTSCHLER: "Arzneimittelwirkungen", 1986, WISSENSCHAFTLICHE VERLAGSGESELLSCHAFT MBH
N.C. ET AL., J CLIN INVEST, vol. 112, 2003, pages 460 - 467
NAKAMURA, T. ET AL., ANAL BIOCHEM, vol. 262, 1998, pages 23 - 32
NEWCOMBE, J. ET AL., NEUROPATHOL APPL NEUROBIOL, vol. 20, 1994, pages 152 - 162
OSTENDORF, J AM SOC NEPHROL., vol. 12, 2001, pages 909 - 918
OSTRESH, METHODS IN ENZYMOLOGY, vol. 267, 1996, pages 220 - 234
PABO, BIOCHEMISTRY, vol. 25, 1986, pages 5987 - 5991
PADDISON, GENES DEV., vol. 16, 2002, pages 948 - 958
PARK, Y.M. ET AL., J CLIN INVEST, vol. 119, 2009, pages 136 - 145
PAUL, NAT. BIOTECHNOL., vol. 20, 2002, pages 505 - 508
PAWLINSKI, R. ET AL., BLOOD, vol. 103, 2004, pages 1342 - 1347
PINHEIRO DA SILVA, F. ET AL., NAT MED, vol. 13, 2007, pages 1368 - 1374
PRAKASH, NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS, vol. 20, 2001, pages 829 - 832
S.H. ET AL., PROC NATL ACAD SCI U S A, vol. 100, 2003, pages 1723 - 1728
SAMANI, ANTISENSE NUCLEIC ACID DRUG DEV, vol. 11, 2001, pages 129 - 136
SAMBROOK; RUSSELL: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY
SAMBROOK; RUSSELL: "Molecular Cloning: A Laboratory Manual", 2001, CSH PRESS
SANDROK, JBC, vol. 276, 2001, pages 35328 - 35333
SAWERS ET AL., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 46, 1996, pages 1 - 9
SCHERR; EDER, CELL CYCLE., vol. 6, no. 4, February 2007 (2007-02-01), pages 444 - 9
SCHWOPE, J ORG CHEM, vol. 64, 1999, pages 4749 - 4761
SEMPLE, BIOCHIM BIOPHYS ACTA, vol. 10, 2001, pages 152 - 166
SODERLING, S.H. ET AL., J NEUROSCI, vol. 27, 2007, pages 355 - 365
SODERLING, S.H. ET AL., PROC NATL ACAD SCI U S A, vol. 100, 2003, pages 1723 - 1728
SODERLING, S.H. ET AL., PROC NATL ACAD SCI USA, vol. 100, 2003, pages 1723 - 1728
SUN, CURR OPIN MOL THER, vol. 2, 2000, pages 100 - 105
SVOBODA, DEVELOPMENT, vol. 127, 2000, pages 4147 - 4156
TAKENAWA, T. ET AL., NATURE REVIEWS, vol. 8, 2007, pages 37 - 48
TAKENAWA, T., NATURE REVIEWS, vol. 8, 2007, pages 37 - 48
TANAKA, NEUROBIOL., vol. 41, 1999, pages 524 - 539
TASKEN, K. & ET AL., A. PHYSIOL REV, vol. 84, 2004, pages 137 - 167
TASKEN, K. ET AL., A. PHYSIOL REV, vol. 84, 2004, pages 137 - 167
TASKEN, K., A. PHYSIOL REV, vol. 84, 2004, pages 137 - 167
TEILLAUD, PATHOL BIOL, vol. 47, 1999, pages 771 - 775
THOMPSON, NUCL. ACIDS RES., vol. 2, 1994, pages 4673 - 4680
TUSCHL T., CHEMBIOCHEM., vol. 2, 2001, pages 239 - 245
UNDERHILL, D.M. ET AL., ANNU REV IMMUNOL, vol. 20, 2002, pages 825 - 852
VOROBJEV, ANTISENSE NUCLEIC ACID DRUG DEV, vol. 11, 2001, pages 77 - 85
WALTON, BIOTECHNOL BIOENG, vol. 65, 2000, pages 1 - 9
WEI, DEV. BIOL., vol. 15, 2000, pages 239 - 255
WESTPHAL RS; SODERLING SH; ALTO NM; LANGEBERG LK; SCOTT JD., EMBO J., vol. 19, no. 17, 1 September 2000 (2000-09-01), pages 4589 - 600
WESTPHAL RS; SODERLING SH; ALTO NM; LANGEBERG LK; SCOTT JD.: "Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold", EMBO J., vol. 19, no. 17, 1 September 2000 (2000-09-01), pages 4589 - 600
WESTPHAL, R.S. ET AL., EMBO J, vol. 19, 2000, pages 4589 - 4600
WICKEL, D.J. ET AL., ANN SURG, vol. 225, 1997, pages 744 - 753
WODAK, ANN. N. Y. ACAD. SCI., vol. 501, 1987, pages 1 - 13
WONG, W. ET AL., NATURE REVIEWS, vol. 5, 2004, pages 959 - 970
YANG, PNAS, vol. 99, 2002, pages 9942 - 9947
YOSHIMI, N. ET AL., LUNG, vol. 183, 2005, pages 109 - 121
YU, PNAS, vol. 99, 2002, pages 6047 - 6052
ZAMORE, NAT STRUCT BIOL, vol. 8, no. 9, 2001, pages 746 - 50
ZHANG ET AL., CURR TOP MED CHEM., vol. 6, no. 9, 2006, pages 893 - 900

Similar Documents

Publication Publication Date Title
Zhuo et al. A loop‐based and AGO‐Incorporated virtual screening model targeting AGO‐Mediated miRNA–mRNA interactions for drug discovery to rescue bone phenotype in genetically modified Mice
Chen et al. Exosome-shuttled circSHOC2 from IPASs regulates neuronal autophagy and ameliorates ischemic brain injury via the miR-7670-3p/SIRT1 axis
Chen et al. Mir30c is involved in diabetic cardiomyopathy through regulation of cardiac autophagy via BECN1
US20190255143A1 (en) Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
JP2018512373A (ja) Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物
Lo et al. Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human
Li et al. Heme induces IL-1β secretion through activating NLRP3 in kidney inflammation
US11739331B2 (en) PARP9 and PARP14 as key regulators of macrophage activation
WO2021185765A1 (fr) Antagoniste de pcsk9
US20080182813A1 (en) UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
Viret et al. Regulation of anti-microbial autophagy by factors of the complement system
Li et al. Sufu limits sepsis-induced lung inflammation via regulating phase separation of TRAF6
Lin et al. Chemically modified small interfering RNA targeting Hedgehog signaling pathway for rheumatoid arthritis therapy
Zhao et al. FC-99 ameliorates sepsis-induced liver dysfunction by modulating monocyte/macrophage differentiation via Let-7a related monocytes apoptosis
US20110229560A1 (en) Nlrc5 as a target for immune therapy
Yang et al. LCC18, a benzamide‐linked small molecule, ameliorates IgA nephropathy in mice
WO2011083147A1 (fr) Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène
JP2011074040A (ja) 膵臓がん治療用の組成物
US8088750B2 (en) Enigma-Mdm2 interaction and uses thereof
Xiong et al. Regulation of postoperative ileus by lentivirus-mediated HuR RNA interference via the p38/MK2 signaling pathway
WO2017197243A1 (fr) Inhibition de cblb pour le traitement d'infections fongiques
KR101099705B1 (ko) ＣＡＮｕ1 단백질 조절을 통한 암세포 생장 억제 및 항암제 민감성 증진제
WO2024097571A1 (fr) Modulateurs de nlrp12 et nlrc5 et leurs procédés d'utilisation pour moduler des maladies
Smith et al. The Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) oncogene is upregulated in pre-cystic epithelial cells revealing a new target for polycystic kidney disease
EP4237561A1 (fr) Traitement d'une maladie cardiovasculaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11700050

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11700050

Country of ref document: EP

Kind code of ref document: A1